Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Hypoxia, Immunometabolism, and Tumor Redox State
2026-09-16
This 2025 review frames tumor hypoxia and immune metabolic reprogramming as a self-reinforcing system that links oxygen limitation, nutrient competition, immune dysfunction, and malignant progression. Its main practical contribution is an integrated framework for designing studies that measure tumor metabolism, immune-cell state, and redox biology together rather than as isolated variables.
-
(R,S)-Anatabine Workflows for Aβ Research
2026-09-16
(R,S)-Anatabine supports mechanism-resolved studies of amyloid precursor protein processing, soluble Aβ peptide reduction, and NF-κB signaling. This workflow guide shows how to integrate Anatabine into neuronal cell assays and short-duration in vivo Alzheimer's disease model studies while controlling solvent, sampling, and interpretation variables.
-
Licoricidin Targets PI3K/AKT in Liver Cancer
2026-09-15
The reference study shows that licoricidin, a prenylated isoflavone from Glycyrrhiza uralensis, inhibits hepatocellular carcinoma cell growth, migration, invasion, and tumor progression in experimental models. Its findings connect apoptosis, S-phase arrest, epithelial–mesenchymal transition, and PI3K/AKT pathway suppression, while also highlighting the need for clinical and mechanistic validation.
-
Sodium Orthovanadate in Translational Insulin Signaling
2026-09-15
Sodium Orthovanadate (Na3VO4) is more than a routine phosphatase additive: its reversible, broad inhibition profile can help preserve phosphorylation-dependent evidence in insulin-resistance research while also creating important assay controls. This article connects mechanism, protocol design, product selection, and translational interpretation around PI-3K/AKT/GLUT4 signaling.
-
URB597 (KDS-4103) in FAAH Research
2026-09-14
URB597 (KDS-4103) offers a selective way to elevate anandamide and isolate FAAH-dependent endocannabinoid biology. This practical guide connects formulation, biochemical target engagement, LC-MS/MS, neuronal assays, and pain-related behavioral workflows while highlighting the limits of translating FAAH inhibition into complex inflammatory models.
-
HyperScript™ Reverse Transcriptase for RNA
2026-09-14
HyperScript™ Reverse Transcriptase is designed for demanding RNA-to-cDNA workflows involving structured transcripts, long targets, or limited input. This practical guide shows how to apply it to qPCR validation and hypothalamic gene-expression studies while improving controls, temperature selection, and troubleshooting.
-
Substance P Workflows for Pain and Inflammation
2026-09-13
Build reproducible Substance P experiments around fresh aqueous handling, receptor-aware controls, and matrix-conscious readouts. This workflow also adapts spectral preprocessing lessons from bioaerosol classification to improve assay quality control without confusing fluorescence signatures with pharmacological evidence.
-
Hesperadin: Aurora B Kinase Inhibitor Workflow
2026-09-12
Hesperadin provides an acute, tunable way to interrogate Aurora B-dependent mitosis, from histone H3 Ser-10 phosphorylation to chromosome segregation and cytokinesis. This workflow combines quantitative dosing, checkpoint-focused controls, and troubleshooting guidance for cell cycle research and cancer research.
-
Camostat Mesilate: Protease & Fibrosis Research
2026-09-11
Camostat Mesilate is a trypsin-like protease inhibitor used to study ENaC function, plasmin-dependent TGF-β signaling, and hepatic fibrosis. Its reported ENaC IC50 is 50 nM, while its fibrosis evidence remains preclinical and should not be conflated with structure-guided antiviral PPI inhibitors.
-
Direct Mouse Genotyping Kit Plus Workflow
2026-09-11
Build a rapid, purification-free mouse genotyping workflow for transgene confirmation, knockout screening, and colony management. The Direct Mouse Genotyping Kit Plus combines direct tissue lysate preparation with a PCR master mix with dye reagents, helping researchers connect genotype decisions to complex experimental phenotypes.
-
Moesin as a Biomarker of Endothelial Injury in Sepsis
2026-09-10
The reference study identifies circulating moesin as a candidate marker of endothelial injury and sepsis severity, linking clinical measurements with mouse and endothelial-cell experiments. Its results connect moesin to Rock1/myosin light chain and NF-κB signaling, while also defining practical limits for translating the findings into mechanistic or therapeutic studies.
-
Idoxuridine: From Viral DNA Mechanism to Translation
2026-09-10
Idoxuridine, also known as 5-iodo-2'-deoxyuridine, is more than a historical antiviral scaffold: it is a practical probe for connecting viral DNA synthesis, replication disruption, and translational assay design. This article outlines how to build stronger evidence around the compound while using human-tissue pharmacology as a model for rigorous target engagement.
-
5-(N,N-dimethyl)-Amiloride: NHE Workflow Guide
2026-09-09
Build sharper intracellular pH, endothelial-barrier, and cardiac ion-transport assays with a concentration-aware NHE workflow. This guide distinguishes evidence from practical recommendations and shows how to interpret DMA alongside moesin, permeability, sodium, and contractility readouts.
-
IPR-803: A Practical Urokinase Receptor Inhibitor
2026-09-09
IPR-803 is a competitive uPAR–uPA interaction blocker for dissecting tumor invasion, metastasis, angiogenesis, and stromal barriers. Its value is strongest in mechanism-led workflows that pair biochemical target engagement with invasion, signaling, pharmacokinetic, or nanomedicine readouts.
-
740 Y-P for Reproducible PI3K/AKT Assays
2026-09-08
This scenario-based guide explains how 740 Y-P (SKU B5246) can support controlled PI3K/AKT pathway activation in cell viability, neuronal survival, cancer, and vesicular trafficking experiments. It covers assay design, stock preparation, interpretation, and practical vendor-selection criteria using product specifications and published pathway evidence.